Latest Ratios: P/E Ratio 39.3x · EV/EBITDA 28.2x · ROE 66.2%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $40.5B | $54.6B | $34.4B | $46.6B | $34.5B | $57.0B | $43.3B | $22.9B | $16.5B | $14.0B | $10.7B |
| Enterprise Value | $41.4B | $55.5B | $35.1B | $47.2B | $35.9B | $57.9B | $44.0B | $23.8B | $17.3B | $15.1B | $11.7B |
| P/E Ratio → | 39.25 | 51.72 | 38.75 | 55.17 | 50.80 | 76.57 | 74.50 | 53.40 | 43.67 | 53.19 | 48.06 |
| P/S Ratio | 9.41 | 12.68 | 8.83 | 12.73 | 10.25 | 17.73 | 16.02 | 9.50 | 7.44 | 7.11 | 6.00 |
| P/B Ratio | 25.80 | 34.00 | 21.57 | 31.40 | 56.70 | 82.62 | 68.51 | 128.55 | — | — | — |
| P/FCF | 38.45 | 51.81 | 43.13 | 60.31 | 87.57 | 89.63 | 80.21 | 75.21 | 59.38 | 47.23 | 39.51 |
| P/OCF | 34.38 | 46.33 | 37.05 | 51.42 | 63.56 | 75.45 | 66.89 | 49.79 | 41.13 | 37.52 | 31.86 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 12.89 | 9.01 | 12.90 | 10.65 | 18.00 | 16.24 | 9.90 | 7.83 | 7.66 | 6.59 |
| EV / EBITDA | 28.23 | 37.83 | 27.91 | 38.96 | 35.49 | 55.85 | 55.62 | 37.20 | 30.17 | 30.39 | 27.32 |
| EV / EBIT | 30.44 | 40.72 | 30.78 | 42.82 | 39.86 | 62.08 | 63.25 | 43.09 | 35.20 | 36.05 | 33.08 |
| EV / FCF | — | 52.66 | 44.00 | 61.10 | 91.01 | 91.02 | 81.36 | 78.44 | 62.54 | 50.85 | 43.39 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.8% | 61.8% | 61.0% | 59.8% | 59.5% | 58.8% | 58.0% | 56.7% | 56.1% | 55.7% | 54.9% |
| Operating Margin | 31.6% | 31.6% | 29.0% | 30.0% | 26.7% | 29.0% | 25.7% | 23.0% | 22.2% | 21.0% | 19.7% |
| Net Profit Margin | 24.6% | 24.6% | 22.8% | 23.1% | 20.2% | 23.2% | 21.5% | 17.8% | 17.0% | 13.4% | 12.5% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 66.2% | 66.2% | 57.7% | 80.7% | 104.6% | 112.6% | 143.5% | 507.4% | — | — | — |
| ROA | 31.9% | 31.9% | 27.1% | 28.1% | 26.2% | 31.5% | 28.2% | 25.4% | 23.2% | 16.2% | 14.8% |
| ROIC | 42.5% | 42.5% | 38.5% | 40.5% | 38.1% | 49.4% | 43.2% | 40.9% | 39.1% | 31.6% | 27.7% |
| ROCE | 61.4% | 61.4% | 49.8% | 57.5% | 56.4% | 55.1% | 49.3% | 59.0% | 66.6% | 63.3% | 57.7% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.67 | 0.67 | 0.62 | 0.72 | 2.41 | 1.49 | 1.59 | 6.02 | — | — | — |
| Debt / EBITDA | 0.73 | 0.73 | 0.78 | 0.88 | 1.45 | 0.99 | 1.27 | 1.67 | 1.74 | 2.54 | 2.81 |
| Net Debt / Equity | — | 0.56 | 0.44 | 0.41 | 2.23 | 1.28 | 0.98 | 5.51 | — | — | — |
| Net Debt / EBITDA | 0.61 | 0.61 | 0.56 | 0.51 | 1.34 | 0.86 | 0.78 | 1.53 | 1.53 | 2.16 | 2.45 |
| Debt / FCF | — | 0.85 | 0.88 | 0.79 | 3.44 | 1.39 | 1.15 | 3.22 | 3.16 | 3.62 | 3.89 |
| Interest Coverage | 35.61 | 35.61 | 36.57 | 26.52 | 22.58 | 31.28 | 20.98 | 17.82 | 14.17 | 11.24 | 11.04 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.17 | 1.17 | 1.31 | 1.57 | 0.89 | 1.25 | 1.82 | 0.94 | 0.85 | 0.97 | 0.90 |
| Quick Ratio | 0.84 | 0.84 | 0.95 | 1.17 | 0.59 | 0.90 | 1.46 | 0.67 | 0.62 | 0.80 | 0.74 |
| Cash Ratio | 0.16 | 0.16 | 0.27 | 0.48 | 0.09 | 0.19 | 0.66 | 0.12 | 0.16 | 0.47 | 0.42 |
| Asset Turnover | — | 1.28 | 1.18 | 1.12 | 1.23 | 1.32 | 1.18 | 1.31 | 1.44 | 1.15 | 1.16 |
| Inventory Turnover | 4.35 | 4.35 | 3.98 | 3.87 | 3.71 | 4.93 | 5.41 | 5.34 | 5.61 | 5.30 | 5.06 |
| Days Sales Outstanding | — | 58.79 | 52.57 | 52.79 | 53.21 | 48.31 | 50.53 | 46.63 | 42.63 | 50.06 | 47.73 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 2.5% | 1.9% | 2.6% | 1.8% | 2.0% | 1.3% | 1.3% | 1.9% | 2.3% | 1.9% | 2.1% |
| FCF Yield | 2.6% | 1.9% | 2.3% | 1.7% | 1.1% | 1.1% | 1.2% | 1.3% | 1.7% | 2.1% | 2.5% |
| Buyback Yield | 3.0% | 2.2% | 2.4% | 0.2% | 2.4% | 1.3% | 0.4% | 1.3% | 2.2% | 2.1% | 2.9% |
| Total Shareholder Yield | 3.0% | 2.2% | 2.4% | 0.2% | 2.4% | 1.3% | 0.4% | 1.3% | 2.2% | 2.1% | 2.9% |
| Shares Outstanding | — | $81M | $83M | $84M | $85M | $87M | $87M | $88M | $88M | $90M | $91M |
Includes 30+ ratios · 30 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying IDXX stock.
IDEXX Laboratories, Inc.'s current P/E ratio is 39.3x. The historical average is 37.6x. This places it at the 61th percentile of its historical range.
IDEXX Laboratories, Inc.'s current EV/EBITDA is 28.2x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 24.2x.
IDEXX Laboratories, Inc.'s return on equity (ROE) is 66.2%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 37.8%.
Based on historical data, IDEXX Laboratories, Inc. is trading at a P/E of 39.3x. This is at the 61th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
IDEXX Laboratories, Inc. has 61.8% gross margin and 31.6% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
IDEXX Laboratories, Inc.'s Debt/EBITDA ratio is 0.7x, indicating low leverage. A ratio below 2x is generally considered financially healthy.
Key Metrics
Top Statement Risk
Corporate consolidation pricing pressure
Metrics are mathematically derived from official filings.
Margin Expansion Driven by Mix Shift
IDEXX's gross margin reached 64.0% in 2026Q2, up 210 bps year-over-year, per reported financials, reflecting a favorable mix toward consumables and software. Operating margin expanded to 35.0%, indicating strong operating leverage.
The sequential improvement in gross margin from 60.3% in 2025Q4 to 64.0% in 2026Q2 suggests that the company is successfully shifting toward higher-margin recurring revenue streams, particularly proprietary consumables and SaaS offerings. Operating margin expansion from 28.9% to 35.0% over the same period indicates that SG&A and R&D costs are scaling slower than gross profit, a sign of operational efficiency. This margin trajectory appears sustainable given the razor-razorblade model, but investors should monitor whether the mix shift can continue without sacrificing volume growth.
ROIC Recovery Signals Compounding Strength
ROIC improved to 12.8% in 2026Q2 from 8.5% in 2024Q4, as per quarterly data, indicating a recovery from a cyclical trough. This suggests the company is compounding returns on invested capital, driven by margin expansion rather than asset turnover.
The 430 bps improvement in ROIC over six quarters is notable, especially given that asset turnover remained relatively flat around 0.36. This indicates that the return enhancement is primarily margin-driven, consistent with the gross margin expansion and operating leverage observed. The trend suggests that IDEXX's capital allocation, including R&D and buybacks, is generating higher returns per dollar invested. However, the absolute ROIC of 12.8% is below the peer average, which may reflect the capital intensity of the reference lab network, but the direction is positive.
Working Capital Efficiency Improves Steadily
Cash conversion cycle improved to 107 days in 2026Q2 from 121 days in 2024Q4, per reported figures, driven by lower DIO and stable DSO. This indicates better inventory management and consistent collection practices.
The reduction in DIO from 95 days to 80 days over the period suggests that IDEXX is managing its consumables inventory more efficiently, possibly due to better demand forecasting. DSO has remained stable around 54 days, indicating consistent collection from veterinary clinics. The slight increase in DPO from 27 to 28 days is marginal, but the overall CCC improvement of 14 days is a positive sign for working capital management. This efficiency may free up cash for reinvestment or shareholder returns, though the absolute CCC remains high due to the nature of the business.
Leverage Comfortable but Rising Slightly
D/E rose to 0.68 in 2026Q2 from 0.62 in 2024Q4, while D/EBITDA fell to 2.35 from 3.34, per reported data, indicating improved debt service capacity. Interest coverage remains strong at 41.98.
The increase in D/E is modest and appears driven by share repurchases that reduced equity, rather than by additional borrowing. The significant improvement in D/EBITDA from 3.34 to 2.35 reflects EBITDA growth outpacing debt, which is a positive signal for creditworthiness. Interest coverage of 41.98 is exceptionally high, suggesting that debt service is not a concern. However, the company's aggressive buyback program, which exceeded FCF in 2026Q2, could increase leverage if debt is used to fund future repurchases, warranting monitoring.
Liquidity Adequate but Cash Buffer Thins
Current ratio improved to 1.17 in 2026Q2 from 1.11 a year earlier, but cash fell to $196.9M from $401.6M in 2024Q2, per reported data. Quick ratio of 0.87 indicates reliance on inventory.
The current ratio remains above 1.0, indicating that current assets cover current liabilities, but the quick ratio of 0.87 suggests that without inventory, liquidity would be strained. The decline in cash is likely due to aggressive share repurchases and capital expenditures, which may limit the company's ability to weather a sudden downturn without accessing credit. Given the strong cash flow generation, this appears manageable, but investors should monitor whether the cash buffer continues to erode.
Misapplied P/E Overlooks Recurring Revenue
The trailing P/E of 43.62 appears elevated, but it fails to capture IDEXX's high-margin recurring revenue model, which justifies a premium. A more appropriate metric is EV/EBITDA, which at 31.30 still reflects growth expectations.
The P/E ratio is often misapplied to IDEXX because it does not account for the company's asset-light, high-margin recurring revenue stream, which is more akin to a software business than a traditional diagnostics manufacturer. The high P/E may deter value investors, but the EV/EBITDA of 31.30, while also high, better reflects the company's operating performance and cash generation. Additionally, the PEG ratio of 3.05 suggests that the market is pricing in significant growth, which may be justified given the accelerating momentum. Investors should focus on EV/EBITDA and FCF yield rather than P/E when evaluating IDEXX.